

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: Better Plant Sciences Inc. (the "Issuer").

Trading Symbol: PLNT

Number of Outstanding Listed Securities: 152,539,000 common shares (plus 81,916,724 common shares reserved for issuance in the form of 64,754,396 warrants and 17,162,328 options).

Date: October 6, 2020

Report on Business

1. **Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.**

In September 2020, the Issuer announced:

- a) it signed an eCommerce lease agreement on August 31, 2020 to take over the day-to-day sales of all Jusu Life Inc. and Jusu Body Inc. products;
- b) the Financial Industry Regulatory Authority, Inc. approved the Issuer's request to change its OTC ticker symbol from BOSQF to VEGGF, effective at the opening of market trading on September 2, 2020;
- c) it's subsidiary Urban Juve Provisions Inc. has completed manufacturing of its hand sanitizer gel and is launching the product in both Canada and the U.S. The hand sanitizer gel is listed with the FDA (NDC 75385-0010-1) and received Natural health Product Number 80098154 from Health Canada;
- d) JUSU Bar juices are available for online order in Calgary through www.jusubaryyc.com for home delivery;
- e) it's subsidiary Wright & Well Essentials Inc. ("**Wright & Well**"), which creates high-end THC and CBD infused topicals and tinctures, was recognized by two leading publications for its packaging design. Packaging of the World and The World of Brand Design Society both featured Wright & Well's packaging online;
- f) JUSU Bar juices are available for online order in Victoria through www.jusubaryyj.com for home delivery;
- g) its majority owned subsidiary NeonMind Biosciences Inc. ("**NeonMind**") has entered into a definitive agreement with Psygen Labs Inc. for the supply of psilocybin for NeonMind's planned preclinical, and clinical trials to study the

use of a drug product including Psilocybin for the treatment of food cravings and anxiety. The agreement was signed on September 28, 2020; and

In September 2020, the Issuer also:

- h) Submitted for approval to Amazon.com (US), a listing for the Urban Juve gel hand sanitizer;
- i) Completed and passed the required third-party testing for our first batch of Urban Juve gel hand sanitizer (certified as an NHP in Canada and registered with the FDA in the US);
- j) Fulfilled orders from our Canadian distributor Ecotrend and various Pharmasave locations for our Urban Juve gel hand sanitizer;
- k) Completed final production preparations with our contract manufacturer for our NeonMind line of mushroom-infused coffees, including reviewing packaging prototypes and receiving raw ingredients;
- l) Completed compliance review and final artwork prior to placing purchase orders for our NeonMind coffee packaging;
- m) Completed due diligence and transition planning for the upcoming purchase of assets from JUSU;
- n) Assumed responsibility for JUSU's e-commerce operations and developed integrated management and reporting (effective Sept 1); and
- o) Continued to add new dispensary customers to carry our Wright & Well line of products in Oregon.

2. Provide a general overview and discussion of the activities of management.

Please see Item 1 above.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

Please see Item 1 above.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

None.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

Please see Item 1 above.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

None.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

Please see Item 1 above.

8. Describe the acquisition of new customers or loss of customers.

Please see Item 1 above.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

Please see Item 1 above.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

None.

11. Report on any labour disputes and resolutions of those disputes if applicable.

None.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

None.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

None.

14. Provide details of any securities issued and options or warrants granted.

Security	Number Issued	Details of Issuance	Use of Proceeds ⁽¹⁾
Special Warrant	2,415,941	September 1, 2020: 2,415,941 special warrants issued pursuant to a private placement at a price of \$0.085 per special warrant. Each special warrant is exercisable without further payment into one unit of the Issuer. Each unit consists of one common share in the capital of the Issuer and one share purchase warrant exercisable at \$0.095 for a period of eight (8) months from the date of issuance for an additional common share in the capital of the Issuer.	Net proceeds of \$199,999.99 to be used as set out in the Prospectus Supplement.
Units	277,777	September 8, 2020: 277,777 units issued at a price of \$0.09 per unit pursuant to Website Lease Agreement. Each unit consists of one common share and one common share purchase warrant exercisable at \$0.11 until September 8, 2022.	Not applicable.
Units	2,415,941	September 10, 2020: 2,415,941 units issued pursuant to the conversion of the 2,415,941 special warrants issued on September 1, 2020. Each unit consists of one common share and one common share purchase warrant exercisable at \$0.95 until May 1, 2021.	Not applicable.
Stock Options	250,000	September 16, 2020: 250,000 stock options granted to employees at an exercise price of \$0.10 per common share for a maximum period of 5 years (or earlier in accordance with the Issuer's stock option plan).	Not applicable.

(1) State aggregate proceeds and intended allocation of proceeds.

15. **Provide details of any loans to or by Related Persons.**

None.

16. **Provide details of any changes in directors, officers or committee members.**

None.

17. **Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.**

On March 11, 2020, the World Health Organization declared COVID-19 a global pandemic. It has adversely affected global workforces, economies, and financial markets, triggering an economic downturn and is expected to impact many retail businesses. It is not possible for the Company to predict the duration or magnitude of the adverse results of the outbreak nor its effects on the Company's business or operations at this time.

The Issuer implemented travel restrictions for work related travel, and imposed self-isolation for employees with symptoms of sickness or returning from international travel. The Issuer also cancelled live multi person events such as in store pop ups and influencer events until further notice.

The Issuer is well-positioned to take advantage of the growing importance placed on physical and mental health and wellbeing, and the rising demand for high-quality, natural products that support this.

The Issuer intends to increase revenues through products that are in high and sustainable consumer demand, drawing on existing, stability-tested formulas to bring these to market under new and existing brands. It has added several hand sanitizer products to its Urban Juve brand, initiated research into topicals that may fight infectious diseases and continues with production plans for its immune boosting mushroom coffee line.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated October 6, 2020.

Penny White
Name of Director or Senior Officer

"Penny White"
Signature

Chief Executive Officer and
President
Official Capacity

Issuer Details Name of Issuer Better Plant Sciences Inc.	For Month End September 2020	Date of Report YY/MM/DD 20/10/06
Issuer Address Suite 200, 1238 Homer Street		
City/Province/Postal Code Vancouver, British Columbia V6B 2Y5	Issuer Fax No. N/A	Issuer Telephone No. 833.514.2677
Contact Name Penny White	Contact Position President, CEO, and Director	Contact Telephone No. 833.514.2677
Contact Email Address penny@betterplantsciences.com	Web Site Address www.betterplantsciences.com	